2-Fluorodeschloroketamine

2-Fluorodeschloroketamine, sold as 2-FDCK, is ketamine with the chlorine on the phenyl ring swapped for fluorine. It is the closest of the widely sold analogues to ketamine itself, in structure and in effect, and it exists for a regulatory reason rather than a pharmacological one: it appeared as ketamine controls tightened, and it functions as a substitute.

The most directly relevant finding is unflattering. In animal work designed to measure abuse liability, 2-FDCK produced responses comparable to ketamine's, which places it in the same category of risk rather than in some milder one ^[7]. It has no medical use, no clinical development history, and no approved status anywhere.

Most of what is documented about it comes from toxicology and public health surveillance rather than pharmacology. It has been identified in clusters of patients presenting after exposure to ketamine and multiple analogues ^[1], measured in wastewater across a southern Chinese province from 2019 to 2021 as a way of tracking how widely it was being used ^[8], and found sold under an entirely different drug's name in powders bought online ^[9]. That last point is the practical one: material sold as something else has turned out to be this, and material sold as this has no verified contents either.

As an NMDA antagonist it impairs coordination and judgment and can cause a dissociative 'hole' at higher doses, with risks of falls, vomiting while sedated, and loss of situational awareness. Frequent use of ketamine-type drugs is linked to bladder and urinary-tract damage and compulsive redosing. It is dangerous combined with other depressants such as alcohol, opioids, or benzodiazepines because of additive sedation. Not medical advice.

2-FDCK emerged around 2018 and spread quickly, in a pattern typical of the ketamine analogue market: ketamine controls tightened, demand did not, and a close structural relative that was not yet named in the relevant schedules filled the space. Its rise was rapid enough to be measurable in wastewater, and monitoring across a southern Chinese province tracked its presence from 2019 through 2021 ^[8]. Residues have been reported in wastewater elsewhere as well ^[10].

The scientific literature that followed is almost entirely analytical and forensic, driven by the need to identify it. Methods were developed to quantify it in blood and hair and to extrapolate its toxicokinetics from in vitro work, because there was no clinical pharmacology to draw on ^[11]. Its metabolic route was mapped across complementary in vitro and in vivo models ^[12], its oxidative and hydrogenation metabolites were characterised and separated by enantiomer ^[13], and the suspected chemical precursor used to make it was identified along with its decomposition products ^[14].

Clinical reports arrived alongside. A cluster of patients exposed to ketamine and multiple analogues was analysed by urinary testing ^[1], and an individual case of intoxication involving several drug classes including 2-FDCK was documented in detail ^[5]. In 2022 an animal study established that its abuse potential is similar to ketamine's ^[7].

2-FDCK is regarded within the dissociative-using community as the nearest available stand-in for ketamine, and that is roughly accurate; it is also the reason it is treated more casually than it warrants. Being similar to ketamine includes being similar in the ways that cause harm, and the one study that set out to measure that found abuse potential comparable to ketamine's rather than reduced ^[7].

The assumption that it is bladder-safer than ketamine circulates and has no published support. No study has examined urinary tract effects of 2-FDCK in people, so the absence of reports reflects the absence of research rather than the absence of harm; that is exactly the reasoning the site treats as invalid.

Among toxicologists its reputation is as an identification problem. It has been found in powders sold as bucinnazine, an unrelated analgesic, which means buyers of other substances have received it unknowingly ^[9], and it shows up in mixed-exposure presentations where attributing an effect to any single compound is not possible ^[1].